

Yaroslau Compta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/690370/publications.pdf>

Version: 2024-02-01

149
papers

10,658
citations

57631

44
h-index

37111

96
g-index

154
all docs

154
docs citations

154
times ranked

11910
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology, The</i> , 2019, 18, 1091-1102.	4.9	1,414
2	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
3	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. <i>Brain</i> , 2011, 134, 1493-1505.	3.7	497
4	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. <i>Lancet Neurology, The</i> , 2014, 13, 575-586.	4.9	436
5	The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). <i>Movement Disorders</i> , 2015, 30, 229-237.	2.2	402
6	Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. <i>Movement Disorders</i> , 2014, 29, 1010-1018.	2.2	297
7	Cognitive impairment and resting-state network connectivity in Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 199-212.	1.9	264
8	Diagnosis and the premotor phase of Parkinson disease. <i>Neurology</i> , 2009, 72, S12-20.	1.5	210
9	Distribution patterns of tau pathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2020, 140, 99-119.	3.9	210
10	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology, The</i> , 2018, 17, 64-74.	4.9	195
11	Functional brain networks and cognitive deficits in Parkinson's disease. <i>Human Brain Mapping</i> , 2014, 35, 4620-4634.	1.9	189
12	Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. <i>Human Brain Mapping</i> , 2012, 33, 2521-2534.	1.9	184
13	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	1.4	178
14	Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2203-2210.	2.2	163
15	Cortical thinning is associated with disease stages and dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 875-882.	0.9	155
16	Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. <i>Brain</i> , 2009, 132, 3308-3317.	3.7	133
17	Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 717-724.	1.1	133
18	Identification of blood serum microRNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2014, 92, 1071-1077.	1.3	122

#	ARTICLE	IF	CITATIONS
19	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
20	Dystonia in Parkinson's disease. <i>Journal of Neurology</i> , 2006, 253, vii7-vii13.	1.8	116
21	REM Sleep Behavior Disorder and Narcoleptic Features in Anti-Ma2-associated Encephalitis. <i>Sleep</i> , 2007, 30, 767-769.	0.6	115
22	Structural correlates of facial emotion recognition deficits in Parkinson's disease patients. <i>Neuropsychologia</i> , 2012, 50, 2121-2128.	0.7	110
23	Cortical thinning associated with mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1495-1503.	2.2	100
24	CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.5	100
25	Resting-state frontostriatal functional connectivity in Parkinson's disease-related apathy. <i>Movement Disorders</i> , 2015, 30, 671-679.	2.2	97
26	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. <i>JAMA Neurology</i> , 2021, 78, 464.	4.5	95
27	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
28	Discriminating cognitive status in Parkinson's disease through functional connectomics and machine learning. <i>Scientific Reports</i> , 2017, 7, 45347.	1.6	88
29	Correlates of cerebrospinal fluid levels of oligomeric- and total- α -synuclein in premotor, motor and dementia stages of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
30	The Significance of α -Synuclein, Amyloid- β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. <i>Neurodegenerative Diseases</i> , 2014, 13, 154-156.	0.8	83
31	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	1.5	78
32	Patterns of cortical thinning in nondemented Parkinson's disease patients. <i>Movement Disorders</i> , 2016, 31, 699-708.	2.2	71
33	Increased CSF levels of IL-1 β , IL-6, and ACE in SARS-CoV-2-associated encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	3.1	69
34	Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. <i>PLoS ONE</i> , 2017, 12, e0183843.	1.1	68
35	Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0132368.	1.1	67
36	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	2.2	66

#	ARTICLE	IF	CITATIONS
37	Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. <i>Journal of Neurochemistry</i> , 2012, 123, 396-405.	2.1	64
38	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. <i>Lancet Neurology</i> , The, 2021, 20, 107-116.	4.9	62
39	Simultaneous low-frequency deep brain stimulation of the substantia nigra pars reticulata and high-frequency stimulation of the subthalamic nucleus to treat levodopa unresponsive freezing of gait in Parkinson's disease: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 153-157.	1.1	59
40	Cortical atrophy patterns in early Parkinson's disease patients using hierarchical cluster analysis. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 3-9.	1.1	57
41	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	2.2	57
42	Long lasting pure freezing of gait preceding progressive supranuclear palsy: A clinicopathological study. <i>Movement Disorders</i> , 2007, 22, 1954-1958.	2.2	54
43	Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. <i>Neuroscience Letters</i> , 2008, 448, 20-23.	1.0	54
44	Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 941-947.	1.1	53
45	Statistical inference in brain graphs using threshold-free network-based statistics. <i>Human Brain Mapping</i> , 2018, 39, 2289-2302.	1.9	53
46	Presentations and mechanisms of CNS disorders related to COVID-19. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	52
47	Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. <i>European Journal of Neurology</i> , 2011, 18, 980-987.	1.7	51
48	Cortical thinning correlates of changes in visuospatial and visuoperceptual performance in Parkinson's disease: A 4-year follow-up. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 62-68.	1.1	51
49	Frequency and Characterization of Movement Disorders in Anti-IgLN5 Disease. <i>Neurology</i> , 2021, 97, .	1.5	50
50	Copathology in Progressive Supranuclear Palsy: Does It Matter?. <i>Movement Disorders</i> , 2020, 35, 984-993.	2.2	48
51	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	2.2	47
52	Excitability of subcortical motor circuits in Go/noGo and forced choice reaction time tasks. <i>Neuroscience Letters</i> , 2006, 406, 66-70.	1.0	45
53	Nigral and striatal connectivity alterations in asymptomatic <i>LRRK2</i> mutation carriers: A magnetic resonance imaging study. <i>Movement Disorders</i> , 2016, 31, 1820-1828.	2.2	45
54	Clinical and imaging markers in premotor <i>LRRK2</i> G2019S mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1170-1176.	1.1	43

#	ARTICLE	IF	CITATIONS
55	Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. <i>Current Opinion in Neurology</i> , 2019, 32, 493-499.	1.8	43
56	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
57	Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 694-697.	1.4	36
58	Amyloid-Î² and Î³, biomarkers in Parkinson's diseaseâ€dementia. <i>Journal of the Neurological Sciences</i> , 2011, 310, 25-30.	0.3	36
59	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 245-247.	1.1	34
60	Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level. <i>NeuroImage: Clinical</i> , 2019, 22, 101720.	1.4	34
61	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	5.8	34
62	The silent period of the thenar muscles to contralateral and ipsilateral deep brain stimulation. <i>Clinical Neurophysiology</i> , 2006, 117, 2512-2520.	0.7	32
63	Brain correlates of progressive olfactory loss in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 44-50.	1.1	32
64	Discovering the 3â€ UTR-mediated regulation of alpha-synuclein. <i>Nucleic Acids Research</i> , 2017, 45, 12888-12903.	6.5	32
65	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 16-23.	1.1	32
66	Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinsonâ€™s disease. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 16-23.	1.1	32
67	Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1405-1410.	1.1	31
68	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. <i>Movement Disorders</i> , 2016, 31, 668-675.	2.2	31
69	Cortical Gray Matter and Hippocampal Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Frontiers in Neurology</i> , 2019, 10, 312.	1.1	31
70	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	2.2	31
71	123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT inÂthe differential diagnosis between vascular parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 192-197.	1.1	30
72	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29

#	ARTICLE	IF	CITATIONS
73	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	2.8	29
74	Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction. <i>Journal of Parkinson's Disease</i> , 2021, 11, 107-121.	1.5	28
75	Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid- β^2 and Tau in Parkinson's Disease I. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1261-1272.	1.2	27
76	Progression of Parkinson's disease patients' subtypes based on cortical thinning: 4-year follow-up. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 286-292.	1.1	27
77	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 5.	2.4	27
78	Lewy and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 451-462.	1.8	26
79	White matter hyperintensities, cerebrospinal amyloid- β^2 and dementia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2016, 367, 284-290.	0.3	26
80	Differential Progression of Regional Hippocampal Atrophy in Aging and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 325.	1.7	26
81	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 3-12.	1.1	26
82	Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 22-27.	1.1	26
83	β -synuclein (<i>SNCA</i>) but not dynamin 3 (<i>DNM3</i>) influences age at onset of leucine-rich repeat kinase 2 (<i>LRRK2</i>) Parkinson's disease in Spain. <i>Movement Disorders</i> , 2018, 33, 637-641.	2.2	25
84	Structural Brain Correlations of Visuospatial and Visuo-perceptual Tests in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 33-44.	1.2	25
85	Differentiation of multiple system atrophy from Parkinson's disease by structural connectivity derived from probabilistic tractography. <i>Scientific Reports</i> , 2019, 9, 16488.	1.6	25
86	Non-motor symptoms in Huntington's disease: a comparative study with Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1340-1350.	1.8	25
87	Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 67-73.	1.1	23
88	Different Cortical Gyrfication Patterns in Alzheimer's Disease and Impact on Memory Performance. <i>Annals of Neurology</i> , 2020, 88, 67-80.	2.8	23
89	Clinical Conditions "Suggestive of Progressive Supranuclear Palsy" Diagnostic Performance. <i>Movement Disorders</i> , 2020, 35, 2301-2313.	2.2	22
90	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	2.2	22

#	ARTICLE	IF	CITATIONS
91	Peripheral insulin and amylin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 91-96.	1.1	20
92	Sex differences in brain atrophy and cognitive impairment in Parkinson's disease patients with and without probable rapid eye movement sleep behavior disorder. <i>Journal of Neurology</i> , 2022, 269, 1591-1599.	1.8	19
93	Human central nervous system circuits examined through the electrodes implanted for deep brain stimulation. <i>Clinical Neurophysiology</i> , 2008, 119, 1219-1231.	0.7	18
94	High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β -amyloid in Parkinson disease. <i>Neuroscience Letters</i> , 2011, 487, 169-173.	1.0	18
95	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
96	<sc>Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior. <i>Brain and Behavior</i> , 2017, 7, e00848.	1.0	17
97	Association of PSP phenotypes with survival: A brain-bank study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 77-81.	1.1	16
98	Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease. <i>Journal of Neurology</i> , 2013, 260, 3002-3009.	1.8	15
99	<sc>MicroRNA</sc> Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways. <i>Movement Disorders</i> , 2020, 35, 1873-1879.	2.2	15
100	Hemichorea as Presentation of Acute Cortical Ischemic Stroke. Case Series and Review of the Literature. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105150.	0.7	15
101	Pure Autonomic Failure With Altered Dopamine Transporter Imaging. <i>Archives of Neurology</i> , 2006, 63, 604.	4.9	14
102	Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ , and $A\beta$ as well as dementia-risk in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 223-229.	0.3	14
103	CCAAT/enhancer binding protein τ is a transcriptional repressor of τ -synuclein. <i>Cell Death and Differentiation</i> , 2020, 27, 509-524.	5.0	14
104	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
105	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	2.2	13
106	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12
107	LRP10 in τ -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	4.9	11
108	Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 23, 101899.	1.4	11

#	ARTICLE	IF	CITATIONS
109	Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry. <i>Journal of Parkinson's Disease</i> , 2021, 11, 685-694.	1.5	10
110	Impaired Structural Connectivity in Parkinson's Disease Patients with Mild Cognitive Impairment: A Study Based on Probabilistic Tractography. <i>Brain Connectivity</i> , 2021, 11, 380-392.	0.8	10
111	Brain atrophy pattern in de novo Parkinson's disease with probable RBD associated with cognitive impairment. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	9
112	Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis. <i>Movement Disorders</i> , 2007, 22, 736-738.	2.2	8
113	Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	8
114	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	1.1	8
115	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson's disease patients. <i>Npj Parkinson's Disease</i> , 2022, 8, 27.	2.5	8
116	Disrupted functional connectivity in PD with probable RBD and its cognitive correlates. <i>Scientific Reports</i> , 2021, 11, 24351.	1.6	8
117	Cystatin C is differentially involved in multiple system atrophy phenotypes. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 507-519.	1.8	7
118	Gray/White Matter Contrast in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 89.	1.7	7
119	Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 951-958.	1.5	7
120	Transcriptomic differences in MSA clinical variants. <i>Scientific Reports</i> , 2020, 10, 10310.	1.6	7
121	Effects of COVID -19 pandemic and lockdown on people with multiple system atrophy participating in a therapeutic education program. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 78-80.	1.1	7
122	Quick outpatient diagnosis in small district or general tertiary hospitals. <i>Medicine (United States)</i> , 2017, 96, e6886.	0.4	6
123	Erratum to "Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study" [<i>Parkinsonism & Related Disorders</i> 19 (2013) 717-724]. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1071-1072.	1.1	4
124	Cerebrospinal fluid levels of alpha-synuclein in PARKINSON'S disease: Another long and winding road. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 1-3.	1.1	4
125	Single-Center Complication Analysis Associated with Surgical Replacement of Implantable Pulse Generators in Deep Brain Stimulation. <i>Stereotactic and Functional Neurosurgery</i> , 2019, 97, 101-105.	0.8	4
126	Differentiation of multiple system atrophy subtypes by gray matter atrophy. <i>Journal of Neuroimaging</i> , 2021, , .	1.0	4

#	ARTICLE	IF	CITATIONS
127	A novel non-rapid-eye movement (REM) and REM parasomnia with sleep breathing disorder associated with antibodies to IgLON5 and tau deposits at post-mortem study. <i>Journal of Neuroimmunology</i> , 2014, 275, 44-45.	1.1	3
128	Malignant Glioma Developed on a Patient Under Deep Brain Stimulation: Pitfalls in Management. <i>World Neurosurgery</i> , 2019, 129, 85-89.	0.7	3
129	Over-Mutated Mitochondrial, Lysosomal and TFEB-Regulated Genes in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 1749.	1.0	3
130	Fatal worsening of late-onset cerebellar ataxia with neuronal intranuclear inclusions due to superimposed meningeal Rosai-Dorfman disease. <i>Movement Disorders</i> , 2008, 23, 1488-1490.	2.2	2
131	The more cortical amyloid β^2 , the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?. <i>Movement Disorders</i> , 2013, 28, 263-264.	2.2	2
132	Conjoint FTLD-tau of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy and Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 352-357.	1.8	2
133	A comparative cost analysis between two quick diagnosis units of different levels of complexity. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 381-392.	0.6	2
134	Primary progressive apraxia of speech: A further piece in the progressive supranuclear/corticobasal degeneration spectrum jigsaw. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 219-220.	1.1	2
135	Deep brain stimulation as a palliative treatment for myorhythmia: A case of failure. <i>European Journal of Neurology</i> , 2022, 29, 937-941.	1.7	2
136	Smoking is associated with age at disease onset in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 79-83.	1.1	2
137	Identifying the genetic components underlying the pathophysiology of movement disorders. <i>The Application of Clinical Genetics</i> , 2011, 4, 81.	1.4	1
138	What goes around comes around: cognitive impairment as prodromal parkinsonism?. <i>Nature Reviews Neurology</i> , 2017, 13, 709-710.	4.9	1
139	Ubiquinone, ubiquinol, 4-hydroxybenzoic acid What is coenzyme Q10? should we care about in multiple system atrophy?. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 117-118.	1.1	1
140	A tear fluid proteome of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 1-2.	1.1	1
141	Setting in motion physiotherapy for MSAp. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 72-73.	1.1	1
142	Quick diagnosis units: predictors of time to diagnosis and costs. <i>Medicine (United States)</i> , 2020, 99, e21241.	0.4	1
143	Non-motor symptoms in spasmodic dysphonia: A case control-study. <i>Auris Nasus Larynx</i> , 2022, 49, 100-105.	0.5	1
144	Insulin-releasing or insulin-sensitizing drugs in Parkinson's disease? Choosing a pathway. <i>Parkinsonism and Related Disorders</i> , 2021, , .	1.1	1

#	ARTICLE	IF	CITATIONS
145	Cross-sectional associations of cerebrospinal α -synuclein, tau and amyloid- β^2 with dyskinesias, motor fluctuations, non-motor symptoms in a cohort of Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120033.	0.3	1
146	Transcriptome analysis in LRRK2 and idiopathic Parkinson's disease at different glucose levels. <i>Npj Parkinson's Disease</i> , 2021, 7, 109.	2.5	1
147	Anticholinergic medications. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 121-125.	1.0	0
148	Enfermedad de Wilson: consideraciones para optimizar el seguimiento a largo plazo. <i>Gastroenterología Y Hepatología</i> , 2021, , .	0.2	0
149	Assessment of Cognitive Symptoms in Brain Bank-Registered Control Subjects: Feasibility and Utility of a Telephone-Based Screening. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1107-1113.	1.2	0